Close Menu

NEW YORK (GenomeWeb) – The Cellworks Group has announced the results of clinical studies that showed how physicians could leverage the firm's computational biology modeling technology for genomic profiling of tumors and predicting patient response to chemotherapies.

In a prospective clinical study, called iCare 1, the Cellworks artificial intelligence-based technology was 90 percent accurate in predicting the response to standard-of-care treatments in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A South African university has told the Wellcome Sanger Institute to return DNA samples it has from indigenous African communities, The Times reports.

The University of California, Berkeley's Rasmus Nielsen and Xinzhu Wei have retracted their CCR5 gene paper due to a technical artifact.

 

University of Virginia researchers are exploring a genetic risk test to gauge type 1 diabetes risk, NPR reports.

In PNAS this week: researchers compare two high-grade neuroendocrine lung cancers, height among ancient Europeans, and more.